REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.
Back to Research Library
semaglutideliraglutide

Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.

May 17, 2026
Share

Source Paper

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino Domenica M et al.JAMA2022
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

Weekly Semaglutide Outperforms Daily Liraglutide in Weight Loss for Non-Diabetic Obese Adults

Published: May 17, 2026 | Source: JAMA (2022) | Category: semaglutide, liraglutide

Overview

A recent study published in the Journal of the American Medical Association (JAMA) has shown that once-weekly subcutaneous semaglutide leads to significantly greater weight loss compared to daily liraglutide among adults with overweight or obesity but without diabetes. This finding is crucial for individuals seeking effective peptide therapies for weight management.

Study Background

Previous research had established the efficacy of both glucagon-like peptide-1 (GLP-1) analogues, semaglutide and liraglutide, in managing body weight. However, direct comparisons between these two treatments were lacking. The STEP 8 trial aimed to address this gap by comparing the effectiveness and safety profiles of once-weekly subcutaneous semaglutide at 2.4 mg versus daily liraglutide at 3.0 mg for weight management in non-diabetic obese adults.

What the Research Found

The study, conducted over a period of 68 weeks, involved 338 participants who were randomized to receive either once-weekly semaglutide (126 participants), daily liraglutide (127 participants), or placebo. The primary outcome was percentage change in body weight from baseline. By the end of the study period, those receiving semaglutide experienced an average weight loss of 15.8%, compared to 6.4% for those on liraglutide, representing a significant difference of -9.4 percentage points (p < 0.001). Additionally, more participants in the semaglutide group achieved clinically meaningful weight loss milestones: 72% reached at least 10% weight loss, compared to 35% for liraglutide.

What This Means for Peptide Users

For individuals looking to manage their body weight through peptide therapy and who do not have diabetes, the results suggest that semaglutide may be a more effective option than daily liraglutide. The once-weekly dosing of semaglutide could also offer greater convenience compared to the daily regimen required for liraglutide.

Limitations and Caveats

While the study provides compelling evidence, it is important to note several limitations. First, the trial had a relatively short follow-up period of 68 weeks, which may not fully capture long-term outcomes or side effects. Second, the study excluded participants with diabetes, limiting its applicability to this population. Lastly, the open-label design might have influenced participant behavior and reporting of adverse events.

How This Compares to Previous Research

Previous studies had shown that both semaglutide and liraglutide were effective in promoting weight loss; however, direct comparisons between these two treatments were limited. The STEP 8 trial provides a definitive comparison, highlighting the superior efficacy of semaglutide for non-diabetic obese adults.

Our Analysis

PeptideVault's analysis indicates that this study offers valuable insights into the comparative effectiveness of once-weekly semaglutide versus daily liraglutide for weight management in non-diabetic individuals. The significant difference in weight loss outcomes supports the potential benefits of semaglutide as a preferred treatment option. However, further research is needed to confirm these findings over longer periods and across diverse populations.

Key Takeaways

  • Greater Efficacy: Once-weekly semaglutide resulted in significantly more weight loss compared to daily liraglutide.
  • Convenience Factor: The once-weekly dosing of semaglutide offers a practical advantage for patients.
  • Further Research Needed: Long-term studies and investigations into the effects on diabetic populations are warranted.

Original Source

Citation: Rubino Domenica M, Greenway Frank L, Khalid Usman et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.. JAMA. DOI: 10.1001/jama.2021.23619

Access: https://pubmed.ncbi.nlm.nih.gov/35015037/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the Peptide Contacts research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

Related Research

Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.

semaglutideGLP-1 receptor agonist

Highlighting the role of peptides in regulating senescence-associated secretory phenotype (SASP) and inflammaging, with a focus on their potential as therapeutic agents for age-related cardiovascular diseases.

liraglutideatrial natriuretic peptiderelaxin mimetics

Highlighting the differential risk profiles of various GLP-1 receptor agonists for gastrointestinal adverse events based on real-world data, emphasizing implications for clinical practice.

GLP-1 receptor agonistsexenatideliraglutide

Comments

Sign in to join the discussion

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.